Skip to main content
. 2011 Oct;2(10):993–995. doi: 10.1177/1947601912437933

Figure 1.

Figure 1.

Efficacy of VB-111 on thyroid cancer–derived xenograft tumors. Intravenous administration of VB-111 to nude mice carrying xenograft tumors using the FTC-derived cells FTC-133 (A), PTC-derived Lam-1 cells (C), or ATC-derived KTC-3 cells (E) resulted in a significant inhibition of tumor growth. Reduction in tumor growth was associated with 2.6-, 2.4-, and 1.8-fold decreased vasculature in FTC-derived (B), PTC-derived (D), and ATC-derived (F) xenografts, respectively, as determined by CD-31 staining. The values in A, C, and E represent means ± SE from 10, 10, and 9 independent tumors each for VB-111 or Ad-PPE treatment. Values in B, D, and F are combined from 15 independent images selected from 3 tumors per group treated with either VB-111 or Ad-PPE, respectively.